CN103958469B - 一种新的普利多匹定盐酸盐多晶型形态 - Google Patents
一种新的普利多匹定盐酸盐多晶型形态 Download PDFInfo
- Publication number
- CN103958469B CN103958469B CN201280043794.9A CN201280043794A CN103958469B CN 103958469 B CN103958469 B CN 103958469B CN 201280043794 A CN201280043794 A CN 201280043794A CN 103958469 B CN103958469 B CN 103958469B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- propyl
- hydrochloride
- metlianesulfonyl
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201170496 | 2011-09-07 | ||
| DKPA201170496 | 2011-09-07 | ||
| US201161533550P | 2011-09-12 | 2011-09-12 | |
| US61/533550 | 2011-09-12 | ||
| PCT/EP2012/067371 WO2013034622A1 (en) | 2011-09-07 | 2012-09-06 | Polymorphic form of pridopidine hydrochloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103958469A CN103958469A (zh) | 2014-07-30 |
| CN103958469B true CN103958469B (zh) | 2016-04-20 |
Family
ID=47831564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280043794.9A Active CN103958469B (zh) | 2011-09-07 | 2012-09-06 | 一种新的普利多匹定盐酸盐多晶型形态 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9006445B2 (https=) |
| EP (1) | EP2753603B1 (https=) |
| JP (2) | JP6189299B2 (https=) |
| KR (1) | KR20140075703A (https=) |
| CN (1) | CN103958469B (https=) |
| AU (1) | AU2012306386B2 (https=) |
| BR (1) | BR112014005389A8 (https=) |
| CA (1) | CA2847736A1 (https=) |
| EA (1) | EA023462B1 (https=) |
| ES (1) | ES2639052T3 (https=) |
| IL (1) | IL231149A0 (https=) |
| MX (1) | MX343620B (https=) |
| WO (1) | WO2013034622A1 (https=) |
| ZA (1) | ZA201402492B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| CN101711236B (zh) | 2007-04-12 | 2012-10-31 | Nsab神经研究瑞典公司分公司 | 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物 |
| JP2013536825A (ja) | 2010-09-03 | 2013-09-26 | イバックス・インターナショナル・ゲーエムベーハー | ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体 |
| TWI579272B (zh) | 2011-12-08 | 2017-04-21 | 梯瓦製藥國際有限責任公司 | 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽 |
| AU2013243461A1 (en) | 2012-04-04 | 2014-11-06 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| HK1221646A1 (zh) * | 2013-06-21 | 2017-06-09 | Teva Pharmaceuticals International Gmbh | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| MX2017008136A (es) | 2014-12-22 | 2018-03-06 | Teva Pharmaceuticals Int Gmbh | Sal de l-tartrato de pridopidina. |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| JP6887952B2 (ja) | 2015-02-25 | 2021-06-16 | プリレニア ニューロセラピューティクス リミテッド | 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用 |
| AR105434A1 (es) * | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| JP7034488B2 (ja) | 2016-02-24 | 2022-03-14 | プリレニア・ニューロセラピューティクス・エルティーディー | プリドピジンを使用する神経変性眼疾患の治療 |
| CA3035099C (en) | 2016-08-24 | 2023-01-17 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating dystonias |
| EP4516356A3 (en) | 2016-08-24 | 2025-05-14 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| CA3050700C (en) | 2017-01-20 | 2023-10-03 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for the treatment of fragile x syndrome |
| EP3357909A1 (en) | 2017-02-02 | 2018-08-08 | Sandoz AG | Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine |
| SI4154882T1 (sl) | 2017-08-14 | 2026-01-30 | Prilenia Neurotherapeutics Ltd. | Zdravljenje amiotrofične lateralne skleroze s pridopidinom |
| CA3073568A1 (en) | 2017-08-30 | 2019-03-07 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
| JP2020533296A (ja) | 2017-09-08 | 2020-11-19 | プリレニア ニューロセラピューティクス リミテッド | 薬物誘発性ジスキネジアを治療するためのプリドピジン |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| CN113395964A (zh) | 2019-02-04 | 2021-09-14 | 普瑞尼亚神经治疗有限公司 | 用于帕金森氏病和与帕金森症相关的其它疾病的低剂量普利多匹定 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| GB0329236D0 (en) * | 2003-12-17 | 2004-01-21 | Arakis Ltd | Crystalline forms of (+)- and (-)- erthro-mefloquine hydrochloride |
| ES2346452T3 (es) | 2004-06-08 | 2010-10-15 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Nuevas fenilpiperidinas/piperazinas disustituidas utilizadas como moduladores de la neurotransmision de la dopamina. |
| CA2584831C (en) * | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| TW200804241A (en) * | 2006-02-24 | 2008-01-16 | Novartis Ag | New salt |
| CN101711236B (zh) | 2007-04-12 | 2012-10-31 | Nsab神经研究瑞典公司分公司 | 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物 |
| WO2008155357A2 (en) | 2007-06-18 | 2008-12-24 | A. Carlsson Research Ab | Use of dopamine stabilizers |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| JP2013536825A (ja) | 2010-09-03 | 2013-09-26 | イバックス・インターナショナル・ゲーエムベーハー | ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体 |
| TWI579272B (zh) | 2011-12-08 | 2017-04-21 | 梯瓦製藥國際有限責任公司 | 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽 |
| AU2013243461A1 (en) | 2012-04-04 | 2014-11-06 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| MX2015003608A (es) | 2012-09-27 | 2015-06-05 | Teva Pharma | Combinacion de laquinimod y pridopidina para tratar trastornos neurodegenerativos. |
| US20150216850A1 (en) | 2012-09-27 | 2015-08-06 | Michael Hayden | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
-
2012
- 2012-09-06 BR BR112014005389A patent/BR112014005389A8/pt not_active IP Right Cessation
- 2012-09-06 AU AU2012306386A patent/AU2012306386B2/en not_active Ceased
- 2012-09-06 JP JP2014528965A patent/JP6189299B2/ja not_active Expired - Fee Related
- 2012-09-06 US US14/342,253 patent/US9006445B2/en active Active
- 2012-09-06 CA CA 2847736 patent/CA2847736A1/en not_active Abandoned
- 2012-09-06 MX MX2014002731A patent/MX343620B/es active IP Right Grant
- 2012-09-06 CN CN201280043794.9A patent/CN103958469B/zh active Active
- 2012-09-06 ES ES12755869.0T patent/ES2639052T3/es active Active
- 2012-09-06 EA EA201490569A patent/EA023462B1/ru not_active IP Right Cessation
- 2012-09-06 KR KR20147009105A patent/KR20140075703A/ko not_active Ceased
- 2012-09-06 WO PCT/EP2012/067371 patent/WO2013034622A1/en not_active Ceased
- 2012-09-06 EP EP12755869.0A patent/EP2753603B1/en active Active
-
2014
- 2014-02-25 IL IL231149A patent/IL231149A0/en unknown
- 2014-04-04 ZA ZA2014/02492A patent/ZA201402492B/en unknown
-
2017
- 2017-05-31 JP JP2017107986A patent/JP2017206516A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014005389A8 (pt) | 2018-04-03 |
| WO2013034622A1 (en) | 2013-03-14 |
| MX343620B (es) | 2016-11-11 |
| ES2639052T3 (es) | 2017-10-25 |
| ZA201402492B (en) | 2015-07-29 |
| KR20140075703A (ko) | 2014-06-19 |
| EP2753603A1 (en) | 2014-07-16 |
| IL231149A0 (en) | 2014-04-30 |
| US9006445B2 (en) | 2015-04-14 |
| AU2012306386B2 (en) | 2017-06-15 |
| BR112014005389A2 (pt) | 2017-03-28 |
| EA201490569A1 (ru) | 2014-09-30 |
| JP6189299B2 (ja) | 2017-08-30 |
| NZ623344A (en) | 2015-10-30 |
| JP2014525470A (ja) | 2014-09-29 |
| JP2017206516A (ja) | 2017-11-24 |
| CN103958469A (zh) | 2014-07-30 |
| CA2847736A1 (en) | 2013-03-14 |
| AU2012306386A1 (en) | 2014-04-17 |
| US20140315951A1 (en) | 2014-10-23 |
| MX2014002731A (es) | 2014-04-30 |
| EA023462B1 (ru) | 2016-06-30 |
| EP2753603B1 (en) | 2017-06-21 |
| HK1199728A1 (en) | 2015-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103958469B (zh) | 一种新的普利多匹定盐酸盐多晶型形态 | |
| WO2020244349A1 (zh) | 呋喃并咪唑并吡啶类化合物的合成方法、多晶型物、及盐的多晶型物 | |
| US20240199544A1 (en) | Crystalline forms of n,n-dimethyltryptamine and methods of using the same | |
| US11124517B2 (en) | Crystal form of Baricitinib and preparation method thereof | |
| US20230120311A1 (en) | Salts and crystalline forms of a taar1 agonist | |
| WO2023091974A2 (en) | Salt and solid forms of (r)-1-(5-methoxy-1 h-indol-1-yl)-n,n-dimethylpropan-2-amine | |
| US20230279017A1 (en) | Salt and solid forms of tabernanthalog | |
| US10513500B2 (en) | Crystalline forms of Lesinurad | |
| TW201811326A (zh) | ４－氰基－ｎ－（２－（４，４－二甲基環己－１－烯－１－基）－６－（２，２，６，６－四甲基四氫－２ｈ－哌喃－４－基）吡啶－３－基）－１ｈ－咪唑－２－甲醯胺之鹽形式 | |
| US11787819B2 (en) | Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof | |
| US9981912B2 (en) | Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof | |
| US20240409501A1 (en) | Cyrstalline forms of rip1 inhibitor | |
| AU2023294116A1 (en) | Crystalline forms of 4-[(5-chloropyridin-2-yl)methoxy]-1-[3-(propan-2-yl)-1h,2h,3h,4h,5h-[1,4]diazepino[1,7-a]indol-9-yl]-1,2-dihydropyridin-2-one and salts thereof, method of preparation, and uses thereof | |
| HK40116055A (zh) | 结构化α-2A肾上腺素受体激动剂的异苯并二氢吡喃-咪唑的新硫酸盐形式 | |
| NZ623344B2 (en) | Polymorphic form of pridopidine hydrochloride | |
| HK1199728B (en) | Polymorphic form of pridopidine hydrochloride | |
| WO2021176216A1 (en) | Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine | |
| WO2018130226A1 (zh) | 利奥西呱的新晶型及其制备方法和用途 | |
| WO2016101912A1 (zh) | 一种表皮生长因子受体激酶抑制剂的盐的晶型及其制备方法 | |
| WO2016082795A1 (zh) | 色瑞替尼的晶型i及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Swiss Qiao Na Applicant after: Taihua international pharmaceutical company Address before: La Perth, Switzerland Applicant before: Nsab AF Neurosearch Sweden Ab |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: NEUROSEARCH A/S TO: TAIHUA PHARMACEUTICAL INTERNATIONAL COMPANY Free format text: CORRECT: ADDRESS; FROM: |
|
| CB02 | Change of applicant information |
Address after: Swiss Qiao Na Applicant after: TEVA PHARMACEUTICALS INTERNATIONAL GMBH Address before: Swiss Qiao Na Applicant before: Taihua international pharmaceutical company |
|
| COR | Change of bibliographic data | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190716 Address after: Israel herzliyya Patentee after: Prilenia Neuropathy Co., Ltd. Address before: Swiss Qiao Na Patentee before: TEVA PHARMACEUTICALS INTERNATIONAL GMBH |